Additional drug resistance of multidrug-resistant tuberculosis in patients in 9 countries

Ekaterina V. Kurbatova; Tracy Dalton; Julia Ershova; Thelma Tupasi; Janice Campos Caoili; Martie Van Der Walt; Charlotte Kvasnovsky; Martin Yagui; Jaime Bayona; Carmen Contreras; Vaira Leimane; Laura E. Via; Heejin Kim; Somsak Akksilp; Boris Y. Kazennyy; Grigory V. Volchenkov; Ruwen Jou; Kai Kliiman; Olga V. Demikhova; J. Peter Cegielski

doi:10.3201/eid2106.141329

Additional drug resistance of multidrug-resistant tuberculosis in patients in 9 countries

Ekaterina V. Kurbatova, Tracy Dalton, Julia Ershova, Thelma Tupasi, Janice Campos Caoili, Martie Van Der Walt, Charlotte Kvasnovsky, Martin Yagui, Jaime Bayona, Carmen Contreras, Vaira Leimane, Laura E. Via, Heejin Kim, Somsak Akksilp, Boris Y. Kazennyy, Grigory V. Volchenkov, Ruwen Jou, Kai Kliiman, Olga V. Demikhova, J. Peter Cegielski

Research output: Contribution to journal › Article › peer-review

13 Scopus citations

Abstract

Data from a large multicenter observational study of patients with multidrug-resistant tuberculosis (MDR TB) were analyzed to simulate the possible use of 2 new approaches to treatment of MDR TB: a short (9-month) regimen and a bedaquiline-containing regimen. Of 1,254 patients, 952 (75.9%) had no resistance to fluoroquinolones and second-line injectable drugs and thus would qualify as candidates for the 9-month regimen; 302 (24.1%) patients with resistance to a fluoroquinolone or second-line injectable drug would qualify as candidates for a bedaquiline-containing regimen in accordance with published guidelines. Among candidates for the 9-month regimen, standardized drug-susceptibility tests demonstrated susceptibility to a median of 5 (interquartile range 5–6) drugs. Among candidates for bedaquiline, drug-susceptibility tests demonstrated susceptibility to a median of 3 (interquartile range 2–4) drugs; 26% retained susceptibility to <2 drugs. These data may assist national TB programs in planning to implement new drugs and drug regimens.

Original language	English
Pages (from-to)	977-983
Number of pages	7
Journal	Emerging Infectious Diseases
Volume	21
Issue number	6
DOIs	https://doi.org/10.3201/eid2106.141329
State	Published - 2015

Bibliographical note

Publisher Copyright:
© 2015 Centers for Disease Control and Prevention (CDC). All rights reserved.

Access to Document

10.3201/eid2106.141329

Cite this

Kurbatova, E. V., Dalton, T., Ershova, J., Tupasi, T., Caoili, J. C., Walt, M. V. D., Kvasnovsky, C., Yagui, M., Bayona, J., Contreras, C., Leimane, V., Via, L. E., Kim, H., Akksilp, S., Kazennyy, B. Y., Volchenkov, G. V., Jou, R., Kliiman, K., Demikhova, O. V., & Peter Cegielski, J. (2015). Additional drug resistance of multidrug-resistant tuberculosis in patients in 9 countries. Emerging Infectious Diseases, 21(6), 977-983. https://doi.org/10.3201/eid2106.141329

@article{e30f1a75acef4157ae283f87cd711a81,

title = "Additional drug resistance of multidrug-resistant tuberculosis in patients in 9 countries",

abstract = "Data from a large multicenter observational study of patients with multidrug-resistant tuberculosis (MDR TB) were analyzed to simulate the possible use of 2 new approaches to treatment of MDR TB: a short (9-month) regimen and a bedaquiline-containing regimen. Of 1,254 patients, 952 (75.9%) had no resistance to fluoroquinolones and second-line injectable drugs and thus would qualify as candidates for the 9-month regimen; 302 (24.1%) patients with resistance to a fluoroquinolone or second-line injectable drug would qualify as candidates for a bedaquiline-containing regimen in accordance with published guidelines. Among candidates for the 9-month regimen, standardized drug-susceptibility tests demonstrated susceptibility to a median of 5 (interquartile range 5–6) drugs. Among candidates for bedaquiline, drug-susceptibility tests demonstrated susceptibility to a median of 3 (interquartile range 2–4) drugs; 26% retained susceptibility to <2 drugs. These data may assist national TB programs in planning to implement new drugs and drug regimens.",

author = "Kurbatova, {Ekaterina V.} and Tracy Dalton and Julia Ershova and Thelma Tupasi and Caoili, {Janice Campos} and Walt, {Martie Van Der} and Charlotte Kvasnovsky and Martin Yagui and Jaime Bayona and Carmen Contreras and Vaira Leimane and Via, {Laura E.} and Heejin Kim and Somsak Akksilp and Kazennyy, {Boris Y.} and Volchenkov, {Grigory V.} and Ruwen Jou and Kai Kliiman and Demikhova, {Olga V.} and {Peter Cegielski}, J.",

year = "2015",

doi = "10.3201/eid2106.141329",

language = "Ingl{\'e}s",

volume = "21",

pages = "977--983",

journal = "Emerging Infectious Diseases",

issn = "1080-6040",

publisher = "Centers for Disease Control and Prevention (CDC)",

number = "6",

}

Kurbatova, EV, Dalton, T, Ershova, J, Tupasi, T, Caoili, JC, Walt, MVD, Kvasnovsky, C, Yagui, M, Bayona, J, Contreras, C, Leimane, V, Via, LE, Kim, H, Akksilp, S, Kazennyy, BY, Volchenkov, GV, Jou, R, Kliiman, K, Demikhova, OV & Peter Cegielski, J 2015, 'Additional drug resistance of multidrug-resistant tuberculosis in patients in 9 countries', Emerging Infectious Diseases, vol. 21, no. 6, pp. 977-983. https://doi.org/10.3201/eid2106.141329

TY - JOUR

T1 - Additional drug resistance of multidrug-resistant tuberculosis in patients in 9 countries

AU - Kurbatova, Ekaterina V.

AU - Dalton, Tracy

AU - Ershova, Julia

AU - Tupasi, Thelma

AU - Caoili, Janice Campos

AU - Walt, Martie Van Der

AU - Kvasnovsky, Charlotte

AU - Yagui, Martin

AU - Bayona, Jaime

AU - Contreras, Carmen

AU - Leimane, Vaira

AU - Via, Laura E.

AU - Kim, Heejin

AU - Akksilp, Somsak

AU - Kazennyy, Boris Y.

AU - Volchenkov, Grigory V.

AU - Jou, Ruwen

AU - Kliiman, Kai

AU - Demikhova, Olga V.

AU - Peter Cegielski, J.

PY - 2015

Y1 - 2015

N2 - Data from a large multicenter observational study of patients with multidrug-resistant tuberculosis (MDR TB) were analyzed to simulate the possible use of 2 new approaches to treatment of MDR TB: a short (9-month) regimen and a bedaquiline-containing regimen. Of 1,254 patients, 952 (75.9%) had no resistance to fluoroquinolones and second-line injectable drugs and thus would qualify as candidates for the 9-month regimen; 302 (24.1%) patients with resistance to a fluoroquinolone or second-line injectable drug would qualify as candidates for a bedaquiline-containing regimen in accordance with published guidelines. Among candidates for the 9-month regimen, standardized drug-susceptibility tests demonstrated susceptibility to a median of 5 (interquartile range 5–6) drugs. Among candidates for bedaquiline, drug-susceptibility tests demonstrated susceptibility to a median of 3 (interquartile range 2–4) drugs; 26% retained susceptibility to <2 drugs. These data may assist national TB programs in planning to implement new drugs and drug regimens.

AB - Data from a large multicenter observational study of patients with multidrug-resistant tuberculosis (MDR TB) were analyzed to simulate the possible use of 2 new approaches to treatment of MDR TB: a short (9-month) regimen and a bedaquiline-containing regimen. Of 1,254 patients, 952 (75.9%) had no resistance to fluoroquinolones and second-line injectable drugs and thus would qualify as candidates for the 9-month regimen; 302 (24.1%) patients with resistance to a fluoroquinolone or second-line injectable drug would qualify as candidates for a bedaquiline-containing regimen in accordance with published guidelines. Among candidates for the 9-month regimen, standardized drug-susceptibility tests demonstrated susceptibility to a median of 5 (interquartile range 5–6) drugs. Among candidates for bedaquiline, drug-susceptibility tests demonstrated susceptibility to a median of 3 (interquartile range 2–4) drugs; 26% retained susceptibility to <2 drugs. These data may assist national TB programs in planning to implement new drugs and drug regimens.

UR - http://www.scopus.com/inward/record.url?scp=84929395533&partnerID=8YFLogxK

U2 - 10.3201/eid2106.141329

DO - 10.3201/eid2106.141329

M3 - Artículo

C2 - 25988299

AN - SCOPUS:84929395533

SN - 1080-6040

VL - 21

SP - 977

EP - 983

JO - Emerging Infectious Diseases

JF - Emerging Infectious Diseases

IS - 6

ER -

Additional drug resistance of multidrug-resistant tuberculosis in patients in 9 countries

Abstract

Bibliographical note

Access to Document

Other files and links

Fingerprint

Cite this